1Department of Vascular Surgery, 4i Centre for Interventions in Infection, Inflammation and Immunity, Graduate Entry Medical School, University of Limerick, Ireland.
Angiology. 2013 Nov;64(8):576-82. doi: 10.1177/0003319712467223. Epub 2012 Nov 27.
Contrast-induced nephropathy (CIN) is a leading cause of hospital-acquired acute kidney injury (AKI). N-acetylcysteine (NAC) was proposed as an effective preventative measure. As data in relation to the use of NAC for the prevention of CIN in peripheral angiography are lacking, a systematic review and meta-analysis were undertaken. A comprehensive search for the published and unpublished data was performed. Data were extracted from the eligible studies. Pooled odds ratios (ORs) were used to calculate the effect of NAC on CIN incidence. Pooled effect size estimates were used to calculate the effect of NAC on serum creatinine (SCr) postcontrast. Our results showed that NAC did not reduce CIN incidence (pooled OR 1.05; 95% confidence interval [CI] 0.38-2.88; P = .92) or the mean SCr levels (pooled weighted mean difference, 4.38; 95% CI 10.4-1.65; P = .15). In conclusion, insufficient evidence exists to recommend NAC for the prevention of CIN in patients undergoing peripheral angiography.
对比剂肾病 (CIN) 是医院获得性急性肾损伤 (AKI) 的主要原因。N-乙酰半胱氨酸 (NAC) 被提议作为一种有效的预防措施。由于外周血管造影中使用 NAC 预防 CIN 的相关数据缺乏,因此进行了系统评价和荟萃分析。对已发表和未发表的数据进行了全面检索。从合格的研究中提取数据。使用汇总优势比 (OR) 计算 NAC 对 CIN 发生率的影响。使用汇总效应量估计值计算 NAC 对造影后血清肌酐 (SCr) 的影响。我们的结果表明,NAC 不能降低 CIN 发生率(汇总 OR 1.05;95%置信区间 [CI] 0.38-2.88;P =.92)或平均 SCr 水平(汇总加权平均差异,4.38;95% CI 10.4-1.65;P =.15)。总之,目前证据不足,无法推荐 NAC 用于预防接受外周血管造影的患者发生 CIN。